drug
(alogliptin benzoate + metformin hydrochloride)
Marketedupdated 2mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 27, 2026
2 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- May 24, 2029formulationUS 89006382.8y
- May 24, 2029formulationUS 89006382.8y
- Jun 27, 2028compositionUS 78076891.9y
- Jun 27, 2028compositionUS 78076891.9y
FDA exclusivities (2)
- Jul 27, 2026M-300Method (3y)2d
- Jul 27, 2026M-300Method (3y)2d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that